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mTOR (mammalian target of rapamycin) stimulates cell growth
by phosphorylating and promoting activation of AGC (protein
kinase A/protein kinase G/protein kinase C) family kinases such
asAkt(proteinkinaseB),S6K(p70ribosomalS6kinase)andSGK
(serum and glucocorticoid protein kinase). mTORC1 (mTOR
complex-1) phosphorylates the hydrophobic motif of S6K,
whereas mTORC2 phosphorylates the hydrophobic motif of Akt
and SGK. In the present paper we describe the small molecule
Ku-0063794, which inhibits both mTORC1 and mTORC2 with
an IC50 of ∼10 nM, but does not suppress the activity of 76 other
protein kinases or seven lipid kinases, including Class
1 PI3Ks (phosphoinositide 3-kinases) at 1000-fold higher
concentrations. Ku-0063794 is cell permeant, suppresses
activation and hydrophobic motif phosphorylation of Akt, S6K
and SGK, but not RSK (ribosomal S6 kinase), an AGC kinase not
regulated by mTOR. Ku-0063794 also inhibited phosphorylation
of the T-loop Thr
308 residue of Akt phosphorylated by PDK1 (3-
phosphoinositide-dependent protein kinase-1). We interpret this
as implying phosphorylation of Ser
473 promotes phosphorylation
of Thr
308 and/or induces a conformational change that protects
Thr
308 from dephosphorylation. In contrast, Ku-0063794 does
not affect Thr
308 phosphorylation in ﬁbroblasts lacking essential
mTORC2 subunits, suggesting that signalling processes have
adapted to enable Thr
308 phosphorylation to occur in the absence
of Ser
473 phosphorylation. We found that Ku-0063794 induced
a much greater dephosphorylation of the mTORC1 substrate
4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) than
rapamycin, even in mTORC2-deﬁcient cells, suggesting a form
of mTOR distinct from mTORC1, or mTORC2 phosphorylates
4E-BP1. Ku-0063794 also suppressed cell growth and induced
aG 1-cell-cycle arrest. Our results indicate that Ku-0063794 will
be useful in delineating the physiological roles of mTOR and
may have utility in treatment of cancers in which this pathway is
inappropriately activated.
Key words: Akt/protein kinase B (PKB), cancer, kinase inhibitor,
phosphoinositide 3-kinase (PI3K), p70 ribosomal S6 kinase
(S6K), serum and glucocorticoid protein kinase (SGK).
INTRODUCTION
The mTOR (mammalian target of rapamycin) protein kinase
lies at the nexus of signalling pathways that regulate cell
growthandproliferation.Manycancer-drivingmutationsingenes
such as receptor tyrosine kinases, Ras, PI3K (phosphoinositide
3-kinase) and PTEN (phosphatase and tensin homologue deleted
on chromosome 10) stimulate proliferation, growth and survival
by activating mTOR kinase. Two mTOR complexes have
been characterized, termed mTORC1 (mTOR complex-1) and
mTORC2 (reviewed in [1,2]). mTORC1 consists of mTOR,
Raptor and mLST8 and is acutely inhibited by rapamycin [3–5].
mTORC1 is activated by insulin and growth factors via a PI3K-
controlled pathway, involving Akt-mediated phosphorylation of
PRAS40 (proline-rich Akt substrate of 40 kDa) and tuberous
sclerosis complex-2 protein, and activation of the Rheb GTPase
[6,7]. mTORC1 is also stimulated by amino acids through a
pathway involving bidirectional transport of amino acids [8] and
the Rag GTPase [9,10]. Low-energy conditions suppress cell
growth by inhibiting mTORC1 via the LKB1–AMPK (AMP-
activated protein kinase) pathway [11]. mTORC2 consists of
mTOR, Rictor, Sin1, mLST8 as well as Protor and is insensitive
to acute rapamycin treatment [12–18]. The activity of mTORC2
activity is controlled by PI3K, but is insensitive to amino acids or
energy stress.
A key role of mTOR complexes is to phosphorylate and
control the activity of a subgroup of related AGC (protein kinase
A/proteinkinaseG/proteinkinaseC)familykinasesthatcomprise
isoforms of Akt, S6K (p70 ribosomal S6 kinase), PKC (protein
kinase C) and SGK (serum and glucocorticoid protein kinase).
mTOR complexes phosphorylate these enzymes at a conserved
C-terminalnon-catalyticresidue,termedthe‘hydrophobicmotif’.
Activation of AGC kinases also requires phosphorylation of
an additional site within their kinase catalytic domain termed
the ‘T-loop motif’. This phosphorylation is executed by the
PDK1 (3-phosphoinositide-dependent protein kinase-1) [19].
mTORC1 phosphorylates the hydrophobic motif of S6K [4,5],
whereas mTORC2 phosphorylates the hydrophobic motifs of Akt
[20], SGK [21] and certain isoforms of PKC [17,22]. In the
case of S6K, SGK and PKC isoforms, hydrophobic motif
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phosphorylation creates a high-afﬁnity docking site for PDK1,
thereby promoting phosphorylation and activation of these
enzymes by PDK1 [19,23]. In the case Akt, interaction of
the PH (pleckstrin homology) domains in PDK1 and Akt with
PtdIns(3,4,5)P3 (a product of PI3K activation), at the plasma
membrane of cells, brings these enzymes together and induces a
conformationalchangeinAktthatenablesittobephosphorylated
at Thr
308 by PDK1 [24,25]. Recent data also indicates that
mTORC2 controls the phosphorylation of Akt and PKC isoforms
at a conserved phosphorylation site termed the ‘turn motif’
that stabilizes these enzymes in an active conformation [26,27].
mTORC1 also phosphorylates other substrates such as the
eukaryotictranslationinitiationfactor4E-BP1[eIF4E(eukaryotic
initiation factor 4E)-binding protein 1]. Phosphorylation of 4E-
BP1 by mTOR induces dissociation from eIF4E, promoting
initiation of protein translation that is required to power cell
growth and proliferation ([4,5],[28], but see [28a]). In the present
study, we describe the characterization of Ku-0063794, a novel
potent and highly speciﬁc small-molecule inhibitor of the mTOR
protein kinase. We demonstrate that Ku-0063794 inhibits both
mTORC1 and mTORC2 in vitro and in vivo and can be employed
to dissect cellular functions of the mTOR pathway.
MATERIALS AND METHODS
Materials
Protein G–Sepharose and glutathione–Sepharose were purchased
from Amersham Bioscience. [γ-
32P]ATP was from PerkinElmer;
IGF1 (insulin-like growth factor) was from Invitrogen. Tween
20, DMSO, PMA and dimethyl pimelimidate were from Sigma,
and CHAPS and rapamycin were from Calbiochem. Akti-1/2,
PI-103 and PD0325901-CL were synthesized by Dr Natalia
Shpiro at the MRC Protein Phosphorylation Unit, University of
Dundee. Ku-0063794 was synthesized at AstraZeneca. The wild-
type control mLST8
+/+ and mLST8
−/− knockout MEFs (mouse
embryonic ﬁbroblasts) were described previously [17] and pro-
vided by David Sabatini (Whitehead Institute for Biomedical
Research, Cambridge, MA, U.S.A.). The wild-type control
Rictor
+/+ and Rictor
−/− knockout MEFs were described pre-
viously [29] and provided by Mark Magnuson (Vanderbilt
UniversitySchoolofMedicine,Nashville,TN,U.S.A.).Thewild-
type control Sin1
+/+ and Sin1
−/− knockout MEFs were described
previously [16] and provided by Bing Su (Yale University School
of Medicine, New Haven, CT, U.S.A.).
Antibodies
The following antibodies were raised in sheep and afﬁnity-
puriﬁed on the appropriate antigen: anti-mLST8 (S837B, 3
rd
bleed) was raised against the human full-length mLST8 protein
expressed in Escherichia coli (used for immunoblotting), anti-
Raptor (S682B, 3
rd bleed; residues 1–20 of human Raptor,
MESEMLQSPLLGLGEEDEAD, used for immunoblotting and
immunoprecipitation), anti-Rictor (S654B, 3
rd bleed; residues
6–20 of human Rictor, RGRSLKNLRVRGRND, used for
immunoblotting in HEK-293 (human embryonic kidney 293)
cells and immunoprecipitation), anti-Rictor (S274C, 1
st bleed;
residues 6–20 of mouse Rictor, RGRSLKNLRIRGRND, used for
immunoblotting), anti-Sin1 (S8C, 1
st bleed) was raised against
the human full-length Sin1 protein expressed in E. coli (used for
immunoblotting). Anti-NDRG1 (N-Myc downstream-regulated
gene-1) (S276B, 2
nd bleed) was made in sheep using recombinant
GST (glutathione transferase) fusion of full-length NDRG1 (used
for immunoblotting). An antibody that recognizes NDRG1
phosphorylated at Thr
346,T h r
356 and Thr
366 (S911B, 2
nd bleed;
termed pNDRG1 3×Thr-P) was raised against the nonapeptide
RSRSHpTSEG, whose sequence is common to all three SGK1
phosphorylation sites on NDGR1 (used for immunoblotting).
Anti-Akt1 (S695B, 3
rd bleed; residues 466 – 480 of human Akt1
RPHFPQFSYSASGTA, used for immunoblotting and immun-
oprecipitation), anti-S6K (S417B, 2
nd bleed; residues 25–44 of
human S6K, AGVFDIDLDQPEDAGSEDEL, used for immun-
oblottingandimmunoprecipitation).Anti-GST(S902A,1
st bleed)
was raised against the GST tag expressed from pGex4T (used for
immunoblotting). Anti-PRAS40 (S115B, 1
st bleed; residues 238–
256 of human PRAS40, DLPRPRLNTSDFQKLKRKY, used
for immunoblotting). An antibody that recognizes PRAS40
phosphorylated at Thr
246 (S114B, 2
nd bleed) was raised against
the residues 240–251 of human PRAS40, CRPRLNTpSDFQK
(used for immunoblotting). Anti-RSK2 (ribosomal S6 kinase 2)
(S382B, 1
st bleed; residues 712–734 of human RNQSPVLEPV-
GRSTLAQRRGIKK, used for immunoblotting and immuno-
precipitation); Anti-FoxO1 (S504A, 1
st bleed) was made in sheep
using recombinant GST-fusion FoxO1 (2–655, used for im-
munoblotting). Anti-β-tubulin (H-235, #sc-9104), phospho-RSK
Thr
227 (#sc-12445-R) and the total mTOR antibody (#sc-1549)
were purchased from Santa Cruz Biotechnology. For phospho-
immunoblotting of the hydrophobic motif of SGK1(Ser
422), we
employed the Thr
389 S6K antibody (# 9205) from Cell Signaling
Technology, which we previously demonstrated cross-reacted
with the phosphorylated Ser
422 of SGK1 [30]. The phospho-
Akt Ser
473 (#9271), Thr
308 (#4056), Thr
450 (#9267), phospho-S6K
Thr
389 (#9234), phospho S6 ribosomal protein Ser
235 (#4856),
total S6 ribosomal protein (#2217), 4E-BP1 total (#9452),
phospho 4E-BP1 Thr
37/Thr
46 (#9459), phospho 4E-BP1 Ser
65
(#9451), phospho-ERK (extracellular-signal-regulated kinase)
Thr
202/Tyr
204 (#9101), total ERK (#9102), phospho-RSK Thr
573
(#9346), phospho-RSK Thr
380 (#9341), phospho-FoxO1/O3
Thr
24/32 (#9464), phospho-GSK3α/β Ser
21/Ser
9 (#9331), the
phospho-mTOR Ser
2481 (#2974) and the phospho-mTOR Ser
2448
(#2971) were purchased from Cell Signaling Technology.
For phospho-immunoblotting of the phosphorylated T-loop of
S6K, we employed the pan-PDK1 site antibody from Cell
Signaling Technology (#9379) as previously described [31].The
GSK3α/β antibody (44–610) was purchased from Biosource.
The secondary antibodies coupled to horseradish peroxidase used
for immunoblotting were obtained from Thermo Scientiﬁc.
General methods
Tissue culture, immunoblotting, restriction enzyme digests, DNA
ligationsandotherrecombinantDNAprocedureswereperformed
using standard protocols. DNA constructs used for transfection
were puriﬁed from E. coli DH5α using Qiagen plasmid Mega
or Maxi kits according to the manufacturer’s protocol. All
DNA constructs were veriﬁed by DNA sequencing, which
was performed by The Sequencing Service, School of Life
Sciences, University of Dundee, Dundee, U.K., using DYEnamic
ET terminator chemistry (Amersham Biosciences) on Applied
Biosystems automated DNA sequencers. For transfection studies,
typically ten 10-cm-diameter dishes of HEK-293 cells were
cultured, and each dish was transfected with 5–10 μgo ft h e
indicated plasmids using the polyethylenimine method [32].
Cellular levels of PtdIns(3,4,5)P3 were measured as described
previously[33].MEFswereculturedwithadditionalnon-essential
amino acids and 1% sodium pyruvate solution.
Buffers
The following buffers were used: Tris lysis buffer [50 mM
Tris/HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 0.3% (w/v)
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CHAPS, 1 mM sodium orthovanadate, 10 mM sodium β-
glycerophosphate, 50 mM sodium ﬂuoride, 5 mM sodium
pyrophosphate, 0.27 M sucrose, 0.15 M NaCl, 0.1% (v/v) 2-
mercaptoethanol,1 mMbenzamidineand0.1 mMPMSF],Buffer
A [50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA and 0.1% (v/v)
2-mercaptoethanol], Hepes lysis buffer [40 mM Hepes, pH 7.5,
120 mM NaCl, 1 mM EDTA, 0.3% (w/v) CHAPS, 10 mM
sodium pyrophosphate, 10 mM sodium β-glycerophosphate,
50 mM sodium ﬂuoride, 0.5 mM sodium orthovanadate, 1 mM
benzamidine and 0.1 mM PMSF], Hepes kinase buf-
fer (25 mM Hepes, pH 7.5, 50 mM KCl and TBS-Tween Buffer
[50 mM Tris/HCl, pH 7.5, 0.15 M NaCl and 0.1% (v/v) Tween
20] and Sample Buffer [50 mM Tris/HCl, pH 6.8, 6.5% (v/v)
glycerol, 1% (w/v) SDS and 1% (v/v) 2-mercaptoethanol].
Cell lysis
HEK-293, HeLa (human cervical carcinoma) or MEF cells were
cultured and treated as described in the Figure legends. Following
treatment, cells were rapidly rinsed twice with ice-cold PBS
and then lysed using Tris lysis buffer. Whole-cell lysates were
centrifuged (18000 g at 4◦C for 20 min), supernatants were re-
moved and stored in aliquots at −80◦C until required.
Speciﬁcity kinase panel
All assays were performed at The National Centre for
Protein Kinase Proﬁling (http://www.kinase-screen.mrc.ac.uk/)
as previously described [34]. Brieﬂy, all assays were carried out
robotically at room temperature (21◦C) and were linear with
respect to time and enzyme concentration under the conditions
used. Assays were performed for 30 min using Multidrop Micro
reagent dispensers (Thermo Electron Corporation, Waltham,
MA, U.S.A.) in a 96-well format. The abbreviations for each
kinase are deﬁned in legend to Table 1. The concentration of
magnesium acetate in the assays was 10 mM and [γ-
33P]ATP
(∼800 c.p.m./pmol) was used at 5 μMf o rC K 2 α, DYRK3,
EF2K, ERK1, ERK8, GSK3β, HIPK2, IGF1R, IRR, MARK3,
MKK1, p38γ MAPK (mitogen-activated protein kinase), p38δ
MAPK, PAK4, PIM2, Akt1, PLK1, PKCζ and PRK2; 20 μMf o r
CaMKKβ,CDK2/cyclinA,CHK1,CHK2,CK1δ,CSK,EPH-B3,
FGF-R1, IR, JNK1α1, JNK2α2, MAPKAP-K2, MSK1, MST2,
MST4, p38β MAPK, PKA, PAK5, PAK6, PDK1, PIM1, PIM3,
PKCα, ROCKII, PRAK, S6K1,SGK1,SYK,VEGFR andYES1;
or50 μMforAMPK,BRSK2,BTK,CaMK1,DYRK1a,DYRK2,
EPH-A2, ERK2, IKKε, LCK, MELK, NEK2A, NEK6, p38α,
PhKγ1, Akt2, PKD1, RSK1, RSK2, SRPK1 and TBK1, in order
to be at or below the Km for ATP for each enzyme [34].
Lipid kinase panel
SPHK1 (sphingosine kinase 1) was assayed as follows: SPHK1
[diluted in 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 5 mM
MgCl2,1 mMEGTAand1 mMDTT(dithiothreitol)]wasassayed
against sphingosine in a ﬁnal volume of 50 μl containing 50 mM
Tris/HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2,1m ME G T A ,
10 μM sphingosine, 10 μM ATP and 1 mM DTT and incubated
for 30 min at room temperature.
SPHK2 was assayed as follows: SPHK2 (diluted in 50 mM
Tris/HCl, pH 7.5, 200 mM KCl, 5 mM MgCl2,1m ME G T Aa n d
1 mM DTT) was assayed against sphingosine in a ﬁnal volume
of 50 μl containing 50 mM Tris/HCl, pH 7.5, 200 mM KCl,
5m MM g C l 2,1m ME G T A ,1 0μM sphingosine, 1 μMA T Pa n d
1 mM DTT and incubated for 30 min at room temperature.
Choline kinase was assayed as follows: choline kinase (diluted
in 25 mM glycine/NaOH, pH 8.5, 67 mM KCl and 5 mM MgCl2)
was assayed against choline in a ﬁnal volume of 50 μl containing
25 mM glycine/NaOH, pH 8.5, 67 mM KCl, 5 mM MgCl2,1m M
choline, 1 μM ATP and 1 mM DTT and incubated for 30 min at
room temperature. These three assays were stopped by addition
of 50 μl Kinase Glo Plus Reagent, incubated for 10 min at room
temperature and read for 1 s/well.
Class 1 PI3Kα w a sa s s a y e da sf o l l o w s :P I 3 K α (diluted in
50 mM Hepes, pH 7.5, 150 mM NaCl, 0.02% sodium cholate
and1 mMDTT)wasassayedagainstPtdIns(4,5)P2 diC8inaﬁnal
volumeof50 μlcontaining37 mMHepes,pH 7.5,111 mMNaCl,
0.02% sodium cholate, 5 mM DTT, 5 mM MgCl2,1m MA T P
and 2 μM PtdIns(4,5)P2 and incubated for 70 min at room
temperature. Assays were stopped by addition of a 5.5 μl
solution of 50 mM EDTA and 0.02% (w/v) sodium cholate.
An aliquot (25 μl) of the resultant mixture was transferred
to a Lumitrac 200 plate. Detection mix 1 [41 mM Hepes,
pH 7.5, 123 mM NaCl, 1.7 μg GST–GRP1 (guanine-nucleotide-
releasing protein 1), 0.16 μM PtdIns(3,4,5)P3–biotin, 1.6 μg
streptavidin–allophycocyanin and 0.96 μg/ml europium-chelate-
labelled antibody] was added to give a ﬁnal volume of 50 μla n d
incubated for 20 min at room temperature before reading.
Class 1 PI3Kβ was assayed as follows: PI3Kβ (diluted in
50 mM Hepes, pH 7.5, 150 mM NaCl, 0.02% sodium cholate
and1 mMDTT)wasassayedagainstPtdIns(4,5)P2–diC8inaﬁnal
volumeof50 μlcontaining37 mMHepes,pH 7.5,111 mMNaCl,
0.02% sodium cholate, 5 mM DTT, 5 mM MgCl2,1m MA T P
and 2 μM PtdIns(4,5)P2 and incubated for 70 min at room
temperature. Assays were stopped by addition of 5.5 μl5 0m M
EDTA and 25 μl assay mixture was transferred to Lumitrac 200
plate. Detection mix 1 was added to give a ﬁnal volume of 50 μl
and the mixture was incubated for 20 min at room temperature
before reading.
Class 2 PI3KC2β was assayed as follows: PI3KC2β (diluted
in 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM DTT, 0.5 mM EGTA and 0.02% CHAPS) was assayed
against phosphoinositide substrate in a ﬁnal volume of 50 μl
containing 19 mM Tris/HCl, pH 7.5, 143 mM NaCl, 0.96 mM
EDTA, 0.96 mM DTT, 0.48 mM EGTA, 0.02% CHAPS,
20 μM phosphatidylinositol, 0.2 mM ATP and 2 mM MgCl2 and
incubated for 30 min at room temperature. Assays were stopped
by addition of 5.5 μl5 0m ME D T Aa n d2% CHAPS, and 25 μl
was transferred to Lumitrac 200 plate. Detection mix 2 (18.6 mM
Tris/HCl, pH 7.5, 140 mM NaCl, 0.9 mM DTT, 0.02% CHAPS,
1.4 μgS G KP X ,0 . 0 6μMP t d I n s 3 P–biotin, 1.6 μg streptavidin–
allophycocyanin and 0.64 μg/ml Eu chelate-labelled antibody)
was added to give a ﬁnal volume of 50 ml and incubated for
30 min at room temperature before reading.
Class 3 VPS34 was assayed as follows: VPS34 (diluted
in 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM DTT, 0.5 mM EGTA and 0.02% CHAPS) was assayed
against phosphoinositide substrate in a ﬁnal volume of 50 μl
containing 19 mM Tris/HCl, pH 7.5, 143 mM NaCl, 0.96 mM
EDTA, 0.96 mM DTT, 0.48 mM EGTA, 0.02% CHAPS,
20 μM phosphatidylinositol, 0.2 mM ATP and 2 mM MnCl2 and
incubated for 60 min at room temperature. Assays were stopped
by addition of 5.5 μl5 0m ME D T Aa n d2% CHAPS and 25 μl
was transferred to a Lumitrac 200 plate. Detection mix 2 was
added to give a ﬁnal volume of 50 ml and incubated for 30 min at
room temperature before reading.
mTOR complexes kinase assays
HEK-293 cells were freshly lysed in Hepes lysis buffer. Lysate
(1–4 mg) was pre-cleared by incubating with 5–20 μl of Protein
G–Sepharose conjugated to pre-immune IgG. The lysate extracts
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Table 1 Effect of Ku-0063794 on 76 protein kinases
Resultsarepresentedaspercentageofkinaseactivitycomparedwithcontrolincubations,inwhichKu-0063794wasomitted.ProteinkinaseswereassayedasdescribedintheMaterialsandmethods
section. The results are an average of a triplicate determination+ −S.D. Asterisks indicate inhibition of >2-fold. Abbreviations not deﬁned in main text: BRSK, brain-speciﬁc kinase; BTK, Bruton’s
tyrosine kinase; CaMK1, calmodulin-dependent kinase; CaMKK, CaMK kinase; CDK, cyclin-dependent kinase; CHK, checkpoint kinase; CK1, casein kinase 1; CSK, C-terminal Src kinase; DYRK,
dual-speciﬁcity tyrosine-phosphorylated and regulated kinase; EF2K, elongation-factor-2 kinase; EPH, ephrin; FGF-R, ﬁbroblast growth factor receptor; GSK3, glycogen synthase kinase 3; HIPK,
homeodomain-interactingproteinkinase;IGF1R,IGF1receptor;IKK,inhibitoryκBkinase;IR,insulinreceptor;IRR,insulin-relatedreceptor;JNK,c-JunN-terminalkinase;Lck,lymphocytecell-speciﬁc
proteintyrosinekinase;MAPKAP-K,MAPK-activatedproteinkinase;MARK,microtubule-afﬁnity-regulatingkinase;MELK,maternalembryonicleucine-zipperkinase;MKK1,MAPKkinase-1;MLCK,
smooth muscle myosin light-chain kinase; MNK, MAPK-integrating protein kinase; MSK, mitogen- and stress-activated protein kinase; MST, mammalian homologue Ste20-like kinase; NEK, NIMA
(never in mitosis in Aspergillus nidulans)-related kinase; PAK, p21-activated protein kinase; PHK, phosphorylase kinase; PIM, provirus integration site for Moloney murine leukaemia virus; PKA,
cAMP-dependent protein kinase; PKD, protein kinase D; PLK, polo-like kinase; PRAK, p38-regulated activated kinase; PRK, protein kinase C-related kinase; ROCK, Rho-dependent protein kinase;
SRPK, serine-arginine protein kinase; SYK, spleen tyrosine kinase; TBK1, TANK-binding kinase 1; VEGFR, vascular endothelial growth factor receptor; YES1, Yamaguchi sarcoma viral oncogene
homologue 1. n.d., not determined.
Percentage of activity remaining Percentage of activity remaining
Kinase Ku-0063794 (1 μM) Ku-0063794 (10μM) Kinase Ku-0063794 (1μM) Ku-0063794 (10μM)
Akt1 98+ −89 0 + −1 MLCK 82+ −4 104+ −3
Akt2 97+ −8 107+ −9 MNK1 111+ −07 5 + −12
AMPK 97+ −1 106+ −3M N K 2 α 87+ −59 2 + −1
Aurora B n.d. 86+ −6 MSK1 101+ −6 117+ −7
BRSK2 90+ −17 2 + −7M S T 2 8 1 + −10 102+ −3
BTK 85+ −78 1 + −21 MST4 87+ −58 6 + −8
CAMK1 96+ −1 101+ −6 NEK2A 92+ −10 86+ −2
CAMKKβ 108+ −59 4 + −0 NEK6 74+ −48 3 + −10
CDK2/Cyclin A 89+ −59 0 + −6 p38α MAPK 101+ −69 6 + −5
CHK1 87+ −88 6 + −7 p38β MAPK 106+ −78 3 + −5
CHK2 97+ −29 6 + −9 p38γ MAPK 89+ −89 1 + −1
CK1δ 112+ −15 109+ −12 p38δ MAPK 72+ −18 7 + −4
CK2α 104+ −08 5 + −12 PAK4 110+ −17 5 + −4
CSK 90+ −19 9 + −3 PAK5 101+ −18 1 + −3
DYRK1a 94+ −10 80+ −7 PAK6 75+ −3 100+ −24
DYRK2 92+ −19 6 + −12 PDK1 89+ −59 1 + −2
DYRK3 88+ −98 4 + −1P h K γ18 9 + −2 116+ −3
EFK2 88+ −7 108+ −0P I M 1 8 9 + −49 8 + −15
EPH-A2 108+ −89 6 + −2P I M 2 8 6 + −11 78+ −0
EPH-B3 100+ −87 8 + −4 PIM3 114+ −12 75+ −7
ERK1 102+ −08 7 + −1 PKA 115+ −78 5 + −12
ERK2 102+ −89 2 + −9 PKCα 106+ −13 86+ −18
ERK8 88+ −19 2 + −5 PKCζ 87+ −98 4 + −0
FGF-R1 102+ −88 7 + −10 PKD1 80+ −4 101+ −3
GSK3β 95+ −11 91+ −5P L K 1 7 6 + −29 4 + −2
HIPK2 89+ −58 9 + −1 PRAK 67+ −48 7 + −8
IGF1R 117+ −08 9 + −1 PRK2 95+ −5 105+ −12
IKKβ 104+ −38 9 + −3 ROCKII 75+ −48 6 + −5
IKKε 99+ −1 100+ −5 RSK1 100+ −48 6 + −2
IR 81+ −16 7 + −5 RSK2 103+ −7 104+ −1
IRR 105+ −77 1 + −4 S6K1 104+ −11 98+ −4
JNK1α18 0 + −59 3 + −4S G K 1 7 6 + −66 4 + −6
JNK2α2 101+ −4 103+ −13 Src n.d. 86+ −5
LCK 69+ −5 104+ −9 SRPK1 101+ −19 4 + −2
MAPKAP-K2 98+ −38 1 + −10 SYK 88+ −38 3 + −5
MARK3 93+ −69 3 + −15 TBK1 97+ −88 9 + −4
MELK 91+ −67 2 + −4 VEGFR 92+ −89 2 + −8
MKK1 96+ −44 3 + −7* YES1 94+ −10 90+ −1
were then incubated with 5–20 μl of Protein G–Sepharose
conjugated to 5–20 μg of either anti-Rictor or anti-Raptor
antibody, or pre-immune IgG. All antibodies were covalently
conjugated to Protein G–Sepharose. Immunoprecipitations were
carried out for 1 h at 4◦C on a vibrating platform. The
immunoprecipitates were washed four times with Hepes lysis
buffer, followed by two washes with Hepes kinase buffer. For
Raptor immunoprecipitates used for phosphorylating S6K1, for
the initial two wash steps the buffer included 0.5 M NaCl
to ensure optimal kinase activity [7]. GST–Akt1 was isolated
from serum-deprived HEK-293 cells incubated with PI-103
(1 μM for 1 h) [24]. GST–S6K1 was puriﬁed from serum-
deprived HEK-293 cells incubated with rapamycin (0.1 μMf o r
1 h) [25]. mTOR reactions were initiated by adding 0.1 mM
ATP and 10 mM MgCl2 in the presence or absence of Ku-
0063794 and GST–Akt1 (0.5 μg) or GST–S6K1 (0.5 μg).
Reaction were carried out for 30 min at 30◦C on a vibrating
platform and stopped by addition of SDS sample buffer.
Reaction mixtures were then ﬁltered through a 0.22-μm-pore-
size Spin-X ﬁlter and samples were subjected to electrophoresis
and immunoblot analysis.
Kinase assays
HEK-293 were lysed in Tris lysis buffer. In order to perform
Akt and S6K assays, 500 μg of lysate was incubated with
5 μg of the corresponding antibody conjugated to Protein G–
Sepharose.ToperformSGK1activityassays,50 μgoftransfected
lysate was incubated with 5 μg of glutathione–Sepharose. All
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Figure 1 Ku-0063794 inhibits both mTORC1 and mTORC2 complexes in vitro
(A)StructureofKu-0063794.(BandC)HEK-293cellextractsweresubjectedtoimmunoprecipitation(IP)withpre-immune(IgG),anti-Raptor(B)oranti-Rictorantibody(C).Theimmunoprecipitates
were incubated with dephosphorylated GST–S6K1 (B) or GST–Akt1 (C) in the presence of the indicated concentrations of Ku-0063794 or vehicle (DMSO). Kinases assays were performed for 30min
in the presence of MgATP and then subjected to immunoblot analysis with the indicated antibodies. Similar results were obtained in three independent experiments. T389-P, phosphorylated Thr389;
S473-P, phosphorylated Ser473.
the incubations were performed for 1 h at 4◦C on a vibrating
platform. Kinase activity was assayed exactly as described
previously [35] using the Crosstide peptide (GRPRTSSFAEG)
at 30 μM. Incorporation of [
32P]phosphate into the peptide
substrate was determined by applying the reaction mixture to
P81 phosphocellulose paper and liquid-scintillation counting of
radioactivityafterwashingthepapersinphosphoricacid.Oneunit
of activity was deﬁned as that which catalysed the incorporation
of 1 nmol of [
32P]phosphate into the substrate.
GST-pull down of transfected SGK1 for immunoblotting analysis
At 36 h post-transfection, HEK-293 cells were lysed in Tris
lysis buffer. Lysate (0.5 mg) was afﬁnity-puriﬁed on glutathione–
Sepharose. Incubations were carried out for 1 h at 4◦Co na
vibrating platform. The resultant precipitates were then washed
twice with Tris lysis buffer containing 0.5 M NaCl, followed
by two washes with Buffer A. The immunoprecipitates were
resuspendedin20 μlofsamplebuffer,ﬁlteredthrougha0.22-μm-
pore-size Spin-X ﬁlter, and samples were subjected to
electrophoresis and immunoblot analysis as described below.
Immunoblotting
Total cell lysate (5–20 μg) or immunoprecipitated samples were
heated at 95◦C for 5 min in sample buffer, and subjected to PAGE
and electrotransfer to nitrocellulose membrane. Membranes were
blocked for 1 h in TBS-Tween buffer containing 10% (w/v) non-
fat dried skimmed milk powder. The membranes were probed
withtheindicatedantibodiesinTBS-Tweencontaining5%(w/v)
skimmed milk or 5% (w/v) BSA for 16 h at 4◦C. Detection was
performed using horseradish peroxidase-conjugated secondary
antibodies and the enhanced chemiluminescence reagent.
Cell growth
MEFs were seeded in 24-well plates (20000 cells per 1.91 cm
2
well) and grown overnight in the presence of 10% foetal bovine
serum. Cells were then treated in the presence or absence or
rapamycin or Ku-0063794 and the medium was changed every
24 h with freshly dissolved inhibitors. Every 24 h of treatment,
cells were washed once with PBS, and ﬁxed in 4% (v/v)
paraformaldehyde in PBS for 15 min. After washing once with
water, the cells were stained with 0.1% Crystal Violet in 10%
ethanol for 20 min and washed three times with water. Crystal
Violetwasextractedfromcellswith0.5 mlof10%(v/v)ethanoic
(acetic)acidfor20 min.Theeluatewasthendiluted1:10inwater,
and absorbance at 590 nm was quantiﬁed.
Flow cytometric analysis of cell cycle distribution
Adherent MEFs were harvested by trypsinization, washed once
in PBS, and re-suspended in ice-cold aq. 70% (v/v) ethanol.
Cells were washed twice in PBS plus 1% (w/v) BSA and stained
for 20 min in PBS plus 0.1% (v/v) Triton X-100 containing
50 g/mlpropidiumiodideand50 g/mlRNaseA.TheDNAcontent
of cells was determined using a FACSCalibur ﬂow cytometer
(BD Biosciences) and CellQuest software. Red ﬂuorescence
(585+ −42 nm) was acquired on a linear scale, and pulse width
analysis was used to exclude doublets. Cell-cycle distribution
was determined using FlowJo software (Tree Star).
RESULTS
Ku-0063794 is a speciﬁc mTORC1 and mTORC2 inhibitor
The structure of Ku-0063794 is shown in Figure 1(A).
It inhibited the activity of endogenous immunoprecipitated
mTORC1, assayed employing S6K1 as substrate (Figure 1B)
and mTORC2, assayed using Akt as substrate (Figure 1C) with
an IC50 of ∼10 nM. To evaluate the speciﬁcity of Ku-0063794,
we studied the effect of Ku-0063794 at ATP concentrations,
which approximate to the Km constant for ATP, towards a panel
of 76 protein kinases. At 1 μM Ku-0063794, which completely
suppressedmTORC1andmTORC2activity(Figures1Band1C),
none of the kinases on the speciﬁcity panel were signiﬁcantly
inhibited (Table 1). Even at 10 μM, the only enzyme on the
panel that was inhibited more than 2-fold was MAPK kinase-1,
which was decreased ∼55% (Table 1). Ku-0063794, even at
concentrations of 10 μM, did not signiﬁcantly inhibit seven lipid
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Table 2 Effect of Ku-0063794 on seven lipid kinases
Results are presented as percentage of lipid kinase activity compared with control incubations
in which Ku-0063794 was omitted. Lipid kinases were assayed as described in the Materials
andmethodssection,intheabsenceorpresenceoftheindicatedconcentrationofKu-0063794.
The results are an average of a triplicate determinations + − S.D.
Percentage of activity remaining
Kinase Ku-0063794 (1μM) Ku-0063794 (10μM)
PI3Ks
Class I
PI3Kα 97+ −29 5 + −3
PI3Kβ 95+ −98 4 + −22
Class II
PI3KC2β 126+ −13 82+ −12
Class III
VPS34 101+ −49 3 + −1
Other lipid kinases
Choline kinase 102+ −1 102+ −1
SPHK1 108+ −39 9 + −7
SPHK2 119+ −2 116+ −3
kinases tested (Class I PI3Kα and PI3Kβ, Class II PI3K-B, Class
III VPS34 as well as SPHK-1, SPHK-2 and choline kinase)
(Table 2).
Ku-0063794 inhibits mTORC1 activity in HEK-293 cells
We next investigated the effect of adding increasing amounts
of Ku-0063794 on the activity and phosphorylation of S6K1 in
HEK-293 cells cultured in the presence of serum (Figure 2A).
Under these conditions, with a concentration of Ku-0063794 as
low as 30 nM, Ku-0063794 almost ablated S6K1 activity and
phosphorylation of the hydrophobic motif (Thr
389). Consistent
withphosphorylationoftheT-loopofS6K1beingdependentupon
prior phosphorylation of the hydrophobic motif, Ku-0063794
inhibited phosphorylation of the T-loop residue (Thr
229). Ku-
0063794 also inhibited phosphorylation of the ribosomal S6
protein, anS6K substrate (Figure2A). Theability ofKu-0063794
to suppress S6K1 activity and phosphorylation was rapid, with
maximal inhibition seen within 10 min and sustained for at least
4 h, the longest time examined (Figure 2B). Ku-0063794 also
suppressed S6K1 activity and phosphorylation induced by IGF1
stimulation of serum-starved HEK-293 cells, although higher
concentrationswererequiredtofullyinhibitS6K1,comparedwith
cells cultured in serum (compare Figure 2A with Figure 2C). For
example,inthepresenceofserum,30 nMKu-0063794suppressed
S6K1 activity by ∼90%, whereas following IGF1 stimulation,
30 nM Ku-0063794 suppressed S6K1 activity by ∼50%.I nt h e
presence of IGF1, a concentration of 300 nM Ku-0063794 was
necessary to reduce S6K1 activity ∼90%. mTORC1, and hence
S6K1, is also activated by nutrients such as amino acids. We
observed that Ku-0063794 induced a dose-dependent inhibition
of the phosphorylation of S6K1 and S6 protein induced following
the replenishment of amino acids to HEK-293 cells incubated
in medium lacking these nutrients (Figure 2D). Concentrations
of 100–300 nM Ku-0063794 were required to fully suppress
amino-acid-induced phosphorylation of S6K1 and S6 protein
(Figure 2D).
Recent work has shown that mTORC1 is phosphorylated at
Ser
2448 [36], a reaction probably mediated by S6K1 [37,38].
In contrast, mTORC2 autophosphorylates at Ser
2481 [36]. We
observed that Ku-0063795 suppressed phosphorylation of both
Ser
2448 and Ser
2481 in a dose-dependent and time-dependent
manner, similar to S6K1 (lower panels of Figures 2A–2C).
Ku-0063794 inhibits mTORC2 activity in HEK-293 cells
To investigate whether Ku-0063794 inhibited mTORC2, we
studiedhowitaffectedAktactivityandhydrophobicmotif(Ser
473)
phosphorylation in HEK-293 cells. In the presence of serum
(Figure 3A) or following IGF1 stimulation (Figure 3B), Ku-
0063794 caused a dose-dependent suppression of Akt activity,
accompaniedbyinhibitionofSer
473 phosphorylation.Asobserved
with S6K1, the activity and phosphorylation of Akt was
inhibited by lower concentrations of Ku-0063794 when cells
were cultured in serum compared with stimulation with IGF1
(compare Figure 3A with Figure 3B). IGF1 induces a ∼6-
fold greater activation of Akt than serum (compare Figure 3A
with Figure 3B), which is likely to account for the higher
concentrations of Ku-0063794 required to inhibit Akt and S6K
in IGF1-stimulated cells compared with serum. The effects of
Ku-0063794 on Akt activity and phosphorylation were observed
within 10 min and were sustained for up to 48 h (Figures 3C
and 3D). Phosphorylation of the Akt substrates PRAS40 at
Thr
246 [39], GSK3α/GSK3β at Ser
21/Ser
9 [40] and Foxo-1/3a
at Thr
24/Thr
32 [41] was also inhibited to a similar extent by Ku-
0063794 as Akt activity and phosphorylation in cells cultured
in serum (Figure 3A). In cells stimulated with IGF1, which
induced a greater activation of Akt than observed with serum,
even concentrations of 1 μM Ku-0063794 did not inhibit Akt
phosphorylation and activation completely (Figure 3B). At 1 μM
Ku-0063794 in IGF-1 stimulated cells, Akt1 activity was reduced
to ∼0.5 units/mg, which is ∼50% of the Akt activity observed
with cells cultured in serum (Figure 3A). This may explain why
phosphorylationofGSK3andFoxoarenotcompletelysuppressed
with 1 μM Ku-00637954 in IGF1-stimulated compared with
serum-treated cells (compare Figure 3A with Figure 3B).
We also studied the effect that Ku-0063794 had on the turn-
motif Thr
450 residue of Akt1, whose phosphorylation is regulated
by mTORC2 [26,27]. Even after 48 h treatment with 1 μMK u -
0063794, phosphorylation of Akt at Thr
450 was only moderately
reduced (Figure 3D). This is consistent with phosphorylation of
Thr
450 being introduced in Akt shortly after its synthesis and
turning over very slowly [26,27].
Ku-0063794 inhibits phosphorylation of Akt at Thr308 in HEK-293
cells
We observed that, in addition to inhibiting Akt Ser
473 phos-
phorylation, Ku-0063794 suppressed phosphorylation of Akt
at Thr
308 (Figures 3A–3D). This was unexpected, as some
previous work suggested that the phosphorylation of Thr
308 by
PDK1 is not directly inﬂuenced by mTORC2. Ku-0063794
was not suppressing Thr
308 phosphorylation by inhibiting PI3K
or PtdIns(3,4,5)P3 production, as IGF1 induced a similar
enhancement of PtdIns(3,4,5)P3 levels in the absence or pre-
sence of 1 μM Ku-0063794, under conditions which the
PI3K inhibitor PI-103 ablated IGF1-induced PtdIns(3,4,5)P3
production (Figure 4A). To further evaluate the effect that
Ku-0063794 had on Thr
308 phosphorylation, we overexpressed
in HEK-293 cells a mutant form of GST–Akt1 in which
Ser
473 was changed to aspartate in an attempt to mimic the
Akt-phosphorylated form of mTORC2 and tested how Ku-
0063794 affected phosphorylation at Thr
308. We found that
IGF1-induced phosphorylation of GST–Akt1(S473D) at Thr
308
was not suppressed by Ku-0063794 to the same extent as
endogenous Akt in these cells, suggesting that Ku-0063794 is
not directly inhibiting PDK1-mediated phosphorylation of Thr
308
(Figure 4B). In parallel studies, Ku-0063794 also suppressed
Thr
308 phosphorylation of wild-type GST–Akt1 to a greater extent
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Figure 2 Ku-0063794 inhibits mTORC1 activity in vivo
(A and B) HEK-293 cells cultured in the presence of 10% foetal bovine serum, were treated for 30min in the absence or presence of the indicated concentrations of Ku-0063794 (A)o rw i t h1μM
Ku-0063794 for the indicated time (B). Cells were lysed and S6K1 immunoprecipitated and catalytic activity assessed employing the Crosstide substrate. Each bar represents the mean speciﬁc
activity + − S.E.M. from three different samples, with each sample assayed in duplicate. Cell lysates were also analysed by immunoblotting with the indicated antibodies. (C)A si n( A), except that
cells were deprived of serum for 16h prior to stimulation with 50ng/ml of IGF-1 for 20min. (D)A si n( C), except that, after 16h of serum deprivation, cells were incubated for 1 h in amino-acid-free
EBSS (Earle’s Balanced Salt Solution) medium containing 10% dialysed serum. Cells were then incubated in the absence or presence or the indicated amount of Ku-0063794 for 30min prior to
re-addition of physiological levels of amino acids for an additional 30 min. Immunoblots are representative of three different experiments.
than GST–Akt1(S473D) (Figure 4B). The dual PI3K and mTOR
inhibitorPI-103inhibitedphosphorylationofThr
308 onbothGST–
Akt1(S473D) and wild-type Akt1 (Figure 4B). We also examined
the effect that Ku-0063794 had on the phosphorylation of Akt at
Thr
308 in MEFs lacking the critical mTORC2 subunits Rictor [29]
(Figure 4C), mLST8 [17] (Figure 4D) and Sin1 [16] (Figure 4E).
Consistent with previous work, IGF1 induced phosphorylation of
Thr
308, but not Ser
473, in mTORC2-deﬁcient cells (Figures 4C–
4E). However, Ku-0063794 did not inhibit phosphorylation of
Thr
308 in any of the mTORC2-deﬁcient cells under conditions
where it suppressed Thr
308 phosphorylation in control wild-type
cells(Figures4C–4E).TreatmentofmTORC2-deﬁcientcellswith
PI-103 abolished phosphorylation of Thr
308.
Ku-0063794 inhibits SGK1 but not RSK
We have shown that SGK1 activity and phosphorylation of
its hydrophobic motif (Ser
422) is regulated by mTORC2 but
not mTORC1 [21]. This ﬁnding has recently been supported
by elegant genetic studies in Caenorhabditis elegans [42,43].
SGK1 activity and hydrophobic motif phosphorylation should
therefore be inhibited by Ku-0063794, but not rapamycin.
As it is not possible to assay phosphorylation and activity
of endogenous SGK1 [21], we investigated how Ku-0063794
affectedactivityandphosphorylationofoverexpressedfull-length
SGK1 in HEK-293 cells cultured in the presence of serum
(Figure 5A). We observed that Ku-0063794 inhibited SGK1
activity and Ser
422 phosphorylation in a dose-dependent manner,
to the same extent as Akt and S6K1 phosphorylation (Figure 5A).
We also examined the phosphorylation of NDRG1, a well-
characterized substrate for SGK1, which is not phosphorylated
in SGK1 knockout mouse tissues [44]. Employing an antibody
recognizing the SGK1-phosphorylated form of NDRG1, we
found that Ku-0063794 inhibited NDRG1 phosphorylation to the
same extent as it suppressed SGK1 activity. Phosphorylation of
endogenous NDRG1 was also inhibited by Ku-0063794 in HeLa
(Figure 5B) cells as well as wild-type MEFs (Figure 5C). The
dual PI3K/mTOR inhibitor PI-103, but not rapamycin or the Akt
inhibitor Akti-1/2 [45], reduced phosphorylation of NDRG1 in
both HeLa cells and wild-type MEFs.
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Figure 3 Ku-0063794 ablates mTORC2 in vivo
HEK-293cellswereculturedinserum,andstimulatedwithIGF-1intheabsenceorpresenceofKu-0063794asdescribedinthelegendtoFigure2.Akt1wasimmunoprecipitatedandcatalyticactivity
assessed employing the Crosstide substrate. Each bar represents the mean speciﬁc activity + − S.E.M. from three different samples, with each sample assayed in duplicate. Cell lysates were analysed
by immunoblotting with the indicated antibodies. Immunoblots are representative of three different experiments. In (D), medium containing freshly dissolved Ku-0063794 was replaced every 12h.
P, phosphorylated.
To ensure Ku-0063794 was not inhibiting the phosphorylation
and activity of all AGC kinases, we studied the effect that
Ku-0063794 had on the activation of the RSK, which is
activated by ERK1/ERK2 pathway and not regulated by mTOR.
HEK-293 cells were stimulated with phorbol ester, which
markedly enhanced ERK as well as RSK phosphorylation and
activity (Figure 5D). Ku-0063794 did not inhibit phorbol ester-
induced ERK or RSK phosphorylation and RSK activation under
conditions in which the MAPK kinase inhibitor PD 0325901-
CL [46] ablated ERK phosphorylation and RSK activation
(Figure 5D).
Ku-0063794 induces complete dephosphorylation of 4E-BP1
Consistent with mTOR regulating 4E-BP1 phosphorylation, we
found that treatment of wild-type MEFs (Figure 6A) or HEK-293
cells (Figure 6B) with Ku-0063794 induced a marked increase in
the electrophoretic mobility of 4E-BP1, which was accompanied
by complete dephosphorylation of Thr
37,T h r
46 and Ser
65.W e
observed that rapamycin reduced phosphorylation of 4E-BP1 and
enhanced electrophoretic mobility to a signiﬁcantly lower extent
than Ku-0063794, even in mTORC2-deﬁcient Sin1 knockout
MEFs (Figures 6A and 6B).
Ku-0063794 suppresses cell growth and induces G1-cell cycle
arrest
We compared the effect that Ku-0063794 and rapamycin had on
growth of wild-type and mLST8 deﬁcient MEFs. We selected
these cells, as despite lacking mTORC2, they proliferate at
similar rates in serum as wild-type control ﬁbroblasts. Moreover,
mLST8-ﬁbroblast cell lines proliferate more rapidly than Rictor-
or Sin1-deﬁcient MEFs (results not shown). We observed that
Ku-0063794 suppressed growth of both wild-type (Figure 7A)
and mLST8-deﬁcient (Figure 7C) MEFs more markedly than
rapamycin. Flow-cytometric analysis indicated that Ku-0063794
increased the proportion of wild-type (Figure 7B) and mLST8
knockout MEFs (Figure 7D) in the G1 cell cycle state approx. 2-
fold, compared with rapamycin, which increased the proportion
of cells in G1 by 1.5-fold.
DISCUSSION
Our results from the present study establish that Ku-0063794
is a potent and highly speciﬁc inhibitor of mTOR as it does
not signiﬁcantly inhibit 76 other protein kinases tested as well
as seven lipid kinases, including class 1a PI3Kα and PI3Kβ.
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Figure 4 Further investigation of the effect of Ku-0063794 on Akt Thr308 phosphorylation
(A) HEK-293cellsweredeprivedofserumfor 16h,treated for 30min in theabsenceor presenceoftheindicatedconcentrationsofKu-0063794orPI-103, thenstimulated with 50 ng/mlofIGF-1 for
10 min. Cell were lysed with 0.5M trichloroacetic acid and amounts of PtdIns(3,4,5)P3 were determined. Each bar represents the means + − S.E.M. from three independent samples. (B) HEK-293
cells were transfected with a DNA construct encoding wild-type or mutant GST–Akt1. At 24h post-transfection, cells were deprived of serum for 16h and stimulated with IGF-1 for 20min, in the
presence or absence of inhibitors as described in (A). Cell lysates were analysed by immunoblotting with the indicated antibodies and immunoblots shown are representative of three separate
experiments. (C–E) The indicated wild-type (wt) or knockout (ko) MEFs were deprived and stimulated with IGF-1 for 20min, in the presence or absence of inhibitors as described in (A). Cell lysates
were analysed by immunoblotting with the indicated antibodies. Similar results were obtained in three independent experiments. P, phosphorylated.
mTOR belongs to the PI3K-related kinases (PIKK) subgroup, as
it possesses signiﬁcant similarity to PI3Ks [47]. Many widely
used PI3K inhibitors, including wortmannin [48], LY294002
[48], PI-103 [49] and NVP-BEZ235 [50], inhibit mTOR with a
potency similar to that towards Class 1 PI3Ks. Recently, speciﬁc
PI3K inhibitors have been described that do not inhibit mTOR,
such as GDC-0941 [51]. Our results from the present study
demonstrate that Ku-0063794 does not inhibit PI3K in vivo,a s
Ku-0063794 does not suppress increases in cellular levels of
PtdIns(3,4,5)P3 following IGF-1 stimulation of HEK-293 cells
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Figure 5 Ku-0063794 suppresses hydrophobic motif phosphorylation and activation of SGK1 but not RSK
(A)HEK-293cellsweretransfectedwithaDNAconstructencodingGST–SGK1(full-lengthenzyme).Cellswereculturedinthepresenceof10%foetalbovineseruminordertomaintainPI3Kpathway
activity. At 36h post-transfection, cells were treated for 30min in the absence or presence of the indicated concentrations of Ku-0063794 or PI-103. Cells were lysed, SGK1 was afﬁnity-puriﬁed
on glutathione–Sepharose and catalytic activity was assessed employing the Crosstide substrate. Each bar represents the mean speciﬁc activity + − S.E.M. from three different samples, with each
sample assayed in duplicate. Afﬁnity puriﬁed SGK1 was also subjected to immunoblotting with an anti-GST antibody (SGK1-Total) as well as an anti-Ser422 phosphospeciﬁc antibody (S422-P). Cell
lysates were also analysed by immunoblotting with the indicated non-SGK antibodies. (B and C) HeLa cells or the indicated wild-type (wt) or knockout (ko) MEFs were cultured in the presence
of 10% serum, then treated for 30min in the absence or presence of the indicated concentrations of inhibitors. Cells were lysed and extracts were analysed by immunoblotting with the indicated
antibodies. Immunoblots are representative of three different experiments. (D) HEK-293 cells were deprived of serum for 16h, treated for 30min in the absence or presence of 1μM Ku-0063794
or 0.2μM PD 0325901 then stimulated with 400ng/ml of PMA for 15min. RSK was immunoprecipitated with an antibody recognizing all isoforms and catalytic activity assessed employing the
Crosstide substrate. Each bar represents the mean speciﬁc activity + − S.E.M. from two different samples, with each sample assayed in duplicate. Cell lysates were also analysed by immunoblotting
with the indicated antibodies. P, phosphorylated.
(Figure 4A). Moreover, Ku-0063794 does not inhibit Akt Thr
308
phosphorylation in three different mTORC2-deﬁcient MEF cell
lines (Figures 4C–4E) under conditions which PI-103 inhibited
PtdIns(3,4,5)P3 production and Thr
308 phosphorylation.
Two other mTOR speciﬁc inhibitors that do not inhibit PI3K
have recently been described, namely PP242 [52] and Torin [53].
Although the chemical structure of Torin has thus far not been
disclosed, the chemical structures of PP242 and Ku-0063794
are quite distinct. We have synthesized PP242 and compared its
speciﬁcity with Ku-0063794 and observed that it is less selective.
At 1 μM PP242, 22 of the 76 kinases tested were inhibited by
>50%, whereas at 10 μM PP242, 46 out of the 76 kinases
were inhibited (results available upon request from D.R.A.).
In contrast, 10 μM Ku-0063794 only suppressed 1 out of 76
kinases over 2-fold (Table 1). Torin was reported to be highly
selective [53]. The availability of chemically unrelated mTOR
inhibitors will be useful in conﬁrming speciﬁcity of physiological
responsesobservedwhenusingthesereagents.Ourﬁndingsusing
Ku-0063794 are similar to those reported for the PP242 [52] and
Torin [53], as all three inhibitors reduced hydrophobic motif as
wellasT-loopphosphorylationofendogenousS6KaswellasAkt.
We also demonstrated Ku-0063794, but not rapamycin or Akti-
1/2, inhibited phosphorylation and activation of SGK1 as well
as its physiological substrate NDGR1. This is consistent with our
ﬁndingsthatSGK1isregulatedbymTORC2andnotthemTORC1
inhibitor rapamycin (reviewed in [54]). We would expect Torin
and PP242 to also inhibit SGK1 activation and phosphorylation.
The ﬁnding that Ku-0063794 as well as Torin [53] and PP242
[52]inhibitedAktThr
308 phosphorylationisarguablyunexpected,
aspreviousworksuggestedthatThr
308 andSer
473 phosphorylation
can occur independently from each other. The initial evidence
for this was that an Akt-T308A mutant overexpressed in
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Figure 6 Ku-0063794 induces a marked dephosphorylation of 4E-BP1
(A and B) The indicated wild-type (wt) or knockout (ko) MEFs (A) or HEK-293 cells (B)w e r e
culturedinthepresenceof10%serum,andtreatedfor30minintheabsenceorpresenceofthe
indicatedconcentrationsofinhibitors.Cellswerelysedandextractsanalysedbyimmunoblotting
with the indicated antibodies. Immunoblots are representative of three different experiments. P,
phosphorylated.
IGF1-stimulated HEK-293 cells was still phosphorylated at
Ser
473 and vice versa [55]. Moreover, in cells lacking mTORC2
activity, Akt is still phosphorylated at Thr
308 despite not being
phosphorylated at Ser
473 [16,17,29]. In PDK1-deﬁcient cells
[56] and in mouse tissues lacking PDK1 [57,58], Akt is still
phosphorylated at Ser
473, but not at Thr
308. One explanation for
the effect that mTOR inhibitors such as Ku-0063794 have on
Akt Thr
308 phosphorylation would be if Akt phosphorylation
of Ser
473 generated a docking site for PDK1 to interact and
phosphorylate Thr
308, in the same way in which phosphorylation
of the hydrophobic motifs of S6K/SGK by mTOR promotes
T-loopphosphorylationoftheseenzymesbyPDK1.Theevidence
against this stems from previous studies undertaken in knockin
cells [59,60] and in mouse tissues [61] that express a PIF-
pocket mutant form of PDK1 that is unable to interact with the
hydrophobicmotifsofS6KandSGK1.Intheseknockinstudies,it
wasdemonstratedthatAktwasnormallyphosphorylatedatThr
308,
under conditions which S6K and SGK are not phosphorylated at
their T-loop residue, suggesting that Akt Thr
308 phosphorylation
was not dependent on PDK1 interacting with Akt via its PIF-
pocket. How can the effects on Thr
308 phosphorylation in mTOR
inhibitor and knockin/knockout studies be reconciled? One
possibility is that in wild-type cells, phosphorylation of Akt at
Ser
473 does indeed promote PDK1 interaction and contributes
towards maximal phosphorylation of Thr
308 by PDK1. However,
in knockout cells permanently lacking mTORC2 activity or in
PDK1 PIF-pocket mutant knockin cells, Akt activation may be
so essential for survival that signalling networks adapt so that
Akt can be phosphorylated by PDK1 at Thr
308 independently
of Ser
473 phosphorylation. Evidence to support the idea that
PDK1 might interact with Ser
473 after its phosphorylation by
mTORC2 might stem from recent observations made in PDK1-
PH domain knockin mice that express a form of PDK1 that
can not interact with PtdIns(3,4,5)P3. In tissues or cells derived
from these animals, Akt is still phosphorylated at Thr
308,a l b e i t
to ∼3-fold lower level than in wild-type tissues or cells [62].
This observation was unexpected, as previous evidence indicated
that PDK1 was needed to interact with phosphoinositides at the
plasma membrane in order to phosphorylate Akt at Thr
308 [19].
However,ifphosphorylationatSer
473 bymTORC2doesstimulate
interactionofPDK1withAkt,thismaybypasstheneedforPDK1
to interact with PtdIns(3,4,5)P3 and enhance phosphorylation of
Thr
308 without the need of PDK1 binding to phosphoinositides. In
future work, it would important to investigate the effect on Akt
Thr
308 phosphorylation of allosteric PIF-pocket PDK1 inhibitors
being elaborated [63,64] or mTORC2-speciﬁc inhibitors (if such
compounds could be developed).
AnotherpossibilitytoaccountfortheeffectofmTORinhibitors
on Akt Thr
308 phosphorylation is if the lack of Akt Ser
473
phosphorylation leads to destabilization of Akt, promoting de-
phosphorylation of Thr
308 by protein phosphatase(s). Indeed, this
idea is supported by structural analysis of Akt2, where it has been
demonstrated that hydrophobic motif phosphorylation induces
a marked disorder-to-order transition of the kinase domain,
resulting in stabilization of the alphaC helix with concomitant
restructuring of the T-loop and reconﬁguration of the structure of
the catalytic domain [65]. Treatment of cells with Ku-0063794
will inhibit Akt Ser
473 phosphorylation and may lead to less stable
Aktconformation,withThr
308 beingmoreexposedandaccessible
to becoming dephosphorylated by protein phosphatase(s). It
would be interesting to investigate whether in mTORC2-deﬁcient
knockout cells, in which Thr
308 phosphorylation is unaffected,
the activity of the protein phosphatase(s) that act on Thr
308 is
reduced, or if Akt is stabilized in some way that enables it to
function without Ser
473 phosphorylation.
Ku-0063794 (Figure 6), as well as Torin [53] and PP242
[52], induce a much greater dephosphorylation of 4E-BP1 than
rapamycin, suggesting that these drugs will more effectively
suppress protein synthesis resulting from overactivation of the
PI3K/Aktpathways.BothmTORC1andmTORC2activitywould
be inhibited in mTORC2-deﬁcient cells treated with rapamycin.
However, we still observed signiﬁcant phosphorylation of 4E-
BP1 at Thr
37/Thr
46 and Ser
65 in Sin-1 knockout MEFs treated
withrapamycin,underconditionsinwhichthehydrophobicmotif
of both S6K and Akt are not phosphorylated (in agreement
with lack of mTORC1 and mTORC2 activity). In contrast,
treatment of Sin-1 knockout MEFs with Ku-0063794 led to a
much greater dephosphorylation of 4E-BP1 than observed with
rapamycin. Similar results were also found with the Torin [53]
and PP242 [52] inhibitors. Taken together, these results indicate
that rapamycin may not inhibit the phosphorylation of 4E-BP1
by mTORC1 and/or there may be a rapamycin-resistant form of
mTOR, distinct from mTORC2. The existence of such a complex
might also explain why Ku-0063794 inhibits proliferation of
mTORC2-deﬁcient mLST8 knockout cells more effectively than
rapamycin (Figures 7C–7D). It would be interesting to see
whether it might be possible to isolate a form of mTOR capable
ofphosphorylating4E-BP1,whichwasinhibitedbyKu-0063794,
but not by rapamycin.
There is great expectation that inhibitors of the PI3K-PDK1-
Akt-mTOR signalling axis will have utility as anti-cancer drugs,
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Figure 7 Ku-0063794 inhibits cell growth and induces a G1 cell cycle arrest
The indicated wild-type (wt) or knockout (ko) MEFs were passaged at low density (20000 cells per 1.91 cm2 dish) and cells were cultured for 1, 2 or 3 days in the absence (DMSO) or presence of
3 μM Ku-0063794 or 100nM rapamycin. (A and C) Cell numbers were measured in quadruplicate using a Crystal Violet staining as described in the Materials and methods section. The results are
presented as means + − S.E.M. of the percentage of cells relative to the DMSO control. Flow cytometric analysis was also undertaken as described in the Materials and methods section. (B and D)
DNA was stained with propidium iodide, and cellular content was analysed. The percentage of cells in G1,S ,o rG 2 phases were determined from triplicate dishes for each condition using CellQuest
software. Two-way ANOVA and Bonferroni posttests were performed, *P <0.001 compared with DMSO control. #P <0.001 compared with rapamycin.
as this signalling network is inappropriately activated in the
majority of human cancers. Rapamycin and its analogues are
being extensively deployed for the treatment of various cancers
[66]. It will be interesting to evaluate whether an inhibitor
such as Ku-0063794, which targets both mTOR complexes, is
a more effective anti-cancer agent than rapamycin. This might
be expected, as mTOR inhibitors such as Ku-0063794, unlike
rapamycin derivatives, will inhibit Akt and SGK isoforms that
are likely to play vital roles in driving the proliferation of
many cancers. The ﬁnding that mTOR inhibitors such as Ku-
0063794 induce more marked dephosphorylation of 4E-BP1 than
rapamycin also holds promise that these drugs will be more
effective at suppressing protein synthesis required for growth
and proliferation of cancer cells than rapamycin derivatives. Ku-
0063794 and other mTOR inhibitors will also be very useful
reagents to dissect and validate the molecular roles that mTOR
plays and hence extend our repertoire of knowledge of how this
master regulator of cell growth operates.
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